0001437749-22-005775.txt : 20220309
0001437749-22-005775.hdr.sgml : 20220309
20220309212135
ACCESSION NUMBER: 0001437749-22-005775
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220224
FILED AS OF DATE: 20220309
DATE AS OF CHANGE: 20220309
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DE GREEF RODERICK
CENTRAL INDEX KEY: 0001241181
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36362
FILM NUMBER: 22727195
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC
CENTRAL INDEX KEY: 0000834365
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 943076866
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
STREET 2: SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 4254011400
MAIL ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
STREET 2: SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: BIOLIFE SOLUTION INC
DATE OF NAME CHANGE: 20030113
FORMER COMPANY:
FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
rdgdoc.xml
FORM 4
X0306
4
2022-02-24
0000834365
BIOLIFE SOLUTIONS INC
BLFS
0001241181
DE GREEF RODERICK
C/O BIOLIFE SOLUTIONS, INC.
3303 MONTE VILLA PARKWAY, SUITE 310
BOTHELL
WA
98021
1
COO & President
Common Stock
2022-02-24
4
A
0
23365
A
115177
D
Restricted Stock Award
0
2022-02-24
4
A
0
23365
0
A
Common Stock
23365
23365
D
The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests on January 3, 2023.
The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.
/s/ Roderick de Greef
2022-03-09